Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

Edogawa NICHE Prize award ceremony honoring Dr Craig Venter to be held in Toronto, Canada.

News provided by

Oct. 20, 2023 16:50

공유
스크랩
인쇄
글자크기
Font Size
- ASmall
- AMedium
- ALarge
- AVery Large

TOKYO--(Business Wire / Korea Newswire)--Harshavardhan Sai Sadineni and Srived Meda of Kasturba Medical College, Manipal, India, won the XVIII Fujio Cup Quiz (FCQ) on Stem cells and Regenerative medicine (RM) in the NCRM NICHE 2023; Sri Ramachandra Institute for Higher Education and Research, India and Institut Teknologi Bandung, Indonesia emerged as runners and joined the team of FCQ elites, a privilege bestowed on those who reach the final stage of the multi-level international contest including a quiz in RM, thereby qualifying to nominate the candidate(s) to Edogawa NICHE Prize, instituted in 2018. The Edogawa NICHE Prize awardee of 2020, Dr John Craig Venter will deliver his lecture at the UHN Ajmera Transplant Center, on the 25th October 2023, in conjunction with the Training Program in Regenerative Medicine (TPRM) at the University of Toronto, co-hosted by German Society for Stem Cell Research (GSZ).

FCQ is an active knowledge gaining event in RM started in 2006 in India, as a part of NCRM NICHE, the inaugural anniversary commemorative event of Nichi-in Centre for Regenerative medicine (NCRM), held every October, conducted in Tokyo 2017~2019, and now virtually. NCRM NICHE has triggered novel ideas and collaborations yielding cutting edge solutions in cell therapies such as the Buccal epithelium Expanded and Encapsulated in Scaffold-Hybrid Approach to Urethral Stricture (BEES HAUS) with clinical studies of safety & efficacy and preclinical evidence, tissue engineering technologies for transplant suitable human chondrocytes for cartilage repair with age reversal in vitro, optimized solutions for transport of cells and tissues for processing between hospitals and cell processing facilities. Through a global inter-disciplinary networking, disease modifying adjunct solutions developed for unmet needs viz., Duchenne muscular dystrophy (DMD), multiple sclerosis (MS), Autism spectrum disorders (ASD), and Parkinson’s disease (PD), were presented in the Inter-disciplinary Conclave (IDC).

Prof. Dr. Mihai G. Netea, Radboud University Medical Center, Netherlands, talked on Trained immunity and innate host defense, Dr Shojiro Katoh, President, Edogawa Hospital, on Novel tissue engineering technology enhancing cell therapies for cartilage repair, Mr. Yasutoshi Nishikawa, on Biomaterials for bone reconstruction and Dr Dedeepiya Devaprasad, on Gut microbiome, Gut-brain-axis & Brain health, moderated by Prof. Dr. Jurgen Hescheler, University of Cologne, Germany.

NCRM with cell biology and biomaterial laboratories, in collaboration with academic and industry partners in Japan are researching on the basic origin of diseases at cellular level taking cues from immune system evolution across phylogeny, in vitro culture systems and in vivo biological responders.

Website: https://www.gncorporation.com/

Contact

GN Corporation Co Ltd
Samuel JK Abraham
info@gncorporation.com

This news is a press release provided by GN Corporation Co., Ltd.. Korea Newswire follows these editorial guidelines.

GN Corporation Co., Ltd. News Releases

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in p...

9월 24일 14:00

뉴리픽스 베타글루칸, 미국 FDA로부터 뒤센 근이영양증 치료제로서 희귀 소아질환 및 희귀 의약품 지정 획득

일본산 뉴리픽스 베타글루칸(Neu REFIX Beta glucan)이 미국 식품의약국(US FDA)으로부터 뒤센 근이영양증(Duchenne muscular Dystrophy, DMD) 치료제로서 희귀 소아 질환 지정(Rare Pediatric Disease Designation, RPDD)과 희귀 의약품 지정(Orphan Drug Designation, ODD)을 모두 획득했다. 이번 지정으로 ...

9월 24일 14:00

... More

More News

All News Releases